TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · IEX Real-Time Price · USD
1.870
-0.050 (-2.60%)
Apr 25, 2024, 3:49 PM EDT - Market closed
Company Description
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States.
It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names.
The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TherapeuticsMD, Inc.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Marlan D. Walker J.D. |
Contact Details
Address: 951 Yamato Road, Suite 220 Boca Raton, Florida 33431 United States | |
| Phone | 561-961-1900 |
| Website | therapeuticsmd.com |
Stock Details
| Ticker Symbol | TXMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000025743 |
| CUSIP Number | 88338N206 |
| ISIN Number | US88338N2062 |
| Employer ID | 87-0233535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Governor Thomas G. Thompson | Executive Chairman |
| Marlan D. Walker J.D. | Chief Executive Officer |
| Robert G. Finizio | Co-Founder |
| Michael C. Donegan | Interim Chief Financial Officer and Chief Accounting Officer |
| Daniella Silva | Chief Compliance Officer |
| Benjamin Foulk | Vice President of Human Resources |
| Bharat Warrier | Chief Manufacturing Officer |
| Douglas Steelman | Vice President of Market Access |
| Dedra Lyden | Vice President of Strategic Partnerships and Initiatives |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 29, 2024 | 8-K | Current Report |
| Dec 6, 2023 | 144 | Filing |
| Nov 17, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Aug 18, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 8-K | Current Report |
| Jul 11, 2023 | D | Notice of Exempt Offering of Securities |